Drug
Linaprazan glurate clinical trials
Also written X842.
Keep track of what changes. Save the linaprazan glurate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Cinclus Pharma Holding AB (7) · Jiangsu Sinorda Biomedicine Co., Ltd (5)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses linaprazan glurate is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan GlurateRecruitingPhase 1Cinclus Pharma Holding ABNCT05469854Written as Linaprazan glurate
- A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)CompletedPhase 3Cinclus Pharma Holding ABNCT07037875Written as Linaprazan glurate 50 mg Twice Daily (BID)
- A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With LansoprazoleCompletedPhase 2Cinclus Pharma Holding ABNCT05055128Written as X842
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose StudyCompletedEarly Phase 1Cinclus Pharma Holding ABNCT03105375Written as Single ascending dose of X842
- Drug Interaction Study on Linaprazan Glurate CapsulesCompletedPhase 1Jiangsu Sinorda Biomedicine Co., LtdNCT07294846Written as Linaprazan Glurate Capsules
- Mass Balance Study of [14C]X842 in Healthy Adult Male SubjectsCompletedPhase 1Jiangsu Sinorda Biomedicine Co., LtdNCT07107672Written as [14C]X842
- The Phase III Clinical Trial of X842 Capsules for Reflux EsophagitisCompletedPhase 3Jiangsu Sinorda Biomedicine Co., LtdNCT07079540Written as X842
- Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux EsophagitisCompletedPhase 2Jiangsu Sinorda Biomedicine Co., LtdNCT04531475Written as X842
- Investigate Linaprazan Glurate/Linaprazan in Healthy SubjectsCompletedPhase 1Cinclus Pharma Holding ABNCT05742984Written as linaprazan glurate 25 mg QD
- Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference FormulationCompletedPhase 1Cinclus Pharma Holding ABNCT05627518Written as Linaprazan glurate
- Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of MidazolamCompletedPhase 1Cinclus Pharma Holding ABNCT05633147Written as Linaprazan glurate
- Single-dose and Multiple-dose X842 Phase 1 StudyCompletedPhase 1Jiangsu Sinorda Biomedicine Co., LtdNCT04293965Written as Single ascending dose of X842
Codes
What other systems call linaprazan glurate · ClinicalTrials.gg INT014744
- UNII (FDA) 3VG4D399DTLINAPRAZAN GLURATEConfirmed FDA, Wikidata
- Wikidata Q117885739linaprazan glurateConfirmed FDA, Wikidata
- NCI Thesaurus C188508Linaprazan GlurateOne source FDA
- DrugBank DB21534One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3VG4D399DT | LINAPRAZAN GLURATE | Confirmed FDA, Wikidata |
| Wikidata | Q117885739 | linaprazan glurate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C188508 | Linaprazan Glurate | One source FDA |
| DrugBank | DB21534 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.